Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

mRNA-1010

- PMLiVE

Moderna’s updated COVID-19 mRNA vaccine approved by MHRA

The updated vaccine will be available to eligible groups as part of the 2026/27 NHS vaccination programme

- PMLiVE

MSD and Moderna announce potential new vaccine for melanoma

The mRNA-based therapy, used with Keytruda, is designed specifically for each patient

- PMLiVE

Moderna appoints Piyali Mukherjee as Head of Medical Affairs, Europe and Middle East

Mukherjee has previously held senior leadership roles at Moderna and GSK

- PMLiVE

Moderna and Merck announce data from melanoma combination therapy study

Skin cancer is one of the most common cancers in the US, with melanoma accounting for the majority of skin cancer deaths

- PMLiVE

Osivax initiates phase 2b trial of influenza A vaccine candidate

The study aims to enrol 2,850 participants across 16 sites in Europe

- PMLiVE

Moderna’s LP.8.1-adapted COVID-19 vaccine recommended by CHMP

Global health authorities have recommended that vaccines for the 2025-2026 season should target LP.8.1

- PMLiVE

Moderna shares positive phase 3 results for mRNA flu vaccine candidate

More than 600,000 people in the US were hospitalised due to flu-related illness last year

- PMLiVE

Moderna’s RSV vaccine mRESVIA granted FDA approval to protect younger adults

The vaccine is already approved in the US for use in adults aged 60 years and older

- PMLiVE

BioNTech expands mRNA capabilities with $1.25bn CureVac acquisition

The deal will support the advancement of BioNTech’s mRNA-based cancer immunotherapies

- PMLiVE

Moderna’s RSV vaccine mRESVIA granted MHRA approval to protect older adults

RSV is responsible for 14,000 hospitalisations per year in UK adults aged 65 years and older

- PMLiVE

Sanofi receives FDA fast track designation for COVID-19/flu combination vaccines

The combined vaccine approach could simplify immunisation practices and lead to higher uptake

- PMLiVE

Seven strategic steps to enhance patient recruitment & retention in your influenza studies

The development of all treatments, including vaccines, is dependent on people taking part in clinical trials but this can be challenging for influenza studies, especially given the typically short patient...

Innovative Trials

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links